...
search icon
evax-img

Evaxion Biotech AS, Common Stock

EVAX

NAQ

$3.7791

-$0.47

(-11.06%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$22.17M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
135.05K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
-0.23
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$3.32 L
$68.05 H
$3.7791

About Evaxion Biotech AS, Common Stock

Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of metastatic melanoma; EVX-02, a DNA-based vaccine that is in Phase 1/2a trial designed to induce a therapeutic immune response in the adjuvant setting in patients with resected melanoma; and EVX-03, DNA-based cancer vaccine for the treatment of various cancers. Its programs also include some vaccines that are in pre-clinical stage, which includes EVX-B1 for the prevention of S. aureus-induced skin and soft tissue infections in patients undergoing elective abdominal hernia surgery; EVX-B2 to target diseases caused by N. gonorrhoeae; EVX-B3 for eliciting strong humoral antibody and cellular immune response to the bacterial pathogen; and EVX-V1, viral vaccine product candidate for targeting Cytomegalovirus. Evaxion Biotech A/S was incorporated in 2008 and is based in Horsholm, Denmark. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameEVAXSectorS&P500
1-Week Return-17.4%0.31%-1.26%
1-Month Return-28.02%0.6%-4.16%
3-Month Return-71.9%-9.44%-0.46%
6-Month Return-76%-5.15%3.58%
1-Year Return-90.49%0.33%22.47%
3-Year Return-98.15%4.53%25.13%
5-Year Return-99.24%35.98%77.7%

Financials

Dec '19Dec '20Dec '21Dec '22Dec '235YR TREND
Total Revenue----73.00K[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Cost of Revenue80.98K105.72K343.45K571.32K112.00[{"date":"2019-12-31","value":14.17,"profit":true},{"date":"2020-12-31","value":18.5,"profit":true},{"date":"2021-12-31","value":60.12,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":0.02,"profit":true}]
Gross Profit(80.98K)(105.72K)(343.45K)(571.32K)72.89K[{"date":"2019-12-31","value":-111.11,"profit":false},{"date":"2020-12-31","value":-145.04,"profit":false},{"date":"2021-12-31","value":-471.21,"profit":false},{"date":"2022-12-31","value":-783.83,"profit":false},{"date":"2023-12-31","value":100,"profit":true}]
Gross Margin(Infinity%)(Infinity%)(Infinity%)(Infinity%)99.85%[{"date":"2019-12-31","value":null,"profit":false},{"date":"2020-12-31","value":null,"profit":false},{"date":"2021-12-31","value":null,"profit":false},{"date":"2022-12-31","value":null,"profit":false},{"date":"2023-12-31","value":100,"profit":true}]
Operating Expenses10.86M16.57M25.83M25.26M22.25M[{"date":"2019-12-31","value":42.05,"profit":true},{"date":"2020-12-31","value":64.13,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":97.79,"profit":true},{"date":"2023-12-31","value":86.11,"profit":true}]
Operating Income(10.86M)(16.57M)(25.83M)(25.26M)(22.20M)[{"date":"2019-12-31","value":-1086300000,"profit":false},{"date":"2020-12-31","value":-1656800000,"profit":false},{"date":"2021-12-31","value":-2583400000,"profit":false},{"date":"2022-12-31","value":-2526400000,"profit":false},{"date":"2023-12-31","value":-2219700000,"profit":false}]
Total Non-Operating Income/Expense(2.37M)(14.00K)2.25M2.65M(3.73M)[{"date":"2019-12-31","value":-89.57,"profit":false},{"date":"2020-12-31","value":-0.53,"profit":false},{"date":"2021-12-31","value":84.96,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-140.89,"profit":false}]
Pre-Tax Income(12.02M)(16.57M)(24.71M)(23.94M)(22.91M)[{"date":"2019-12-31","value":-1202000000,"profit":false},{"date":"2020-12-31","value":-1657500000,"profit":false},{"date":"2021-12-31","value":-2471000000,"profit":false},{"date":"2022-12-31","value":-2394100000,"profit":false},{"date":"2023-12-31","value":-2291500000,"profit":false}]
Income Taxes(825.00K)(1.56M)(178.00K)(772.00K)(791.22K)[{"date":"2019-12-31","value":-82500000,"profit":false},{"date":"2020-12-31","value":-155700000,"profit":false},{"date":"2021-12-31","value":-17800000,"profit":false},{"date":"2022-12-31","value":-77200000,"profit":false},{"date":"2023-12-31","value":-79121500,"profit":false}]
Income After Taxes(11.20M)(15.02M)(24.53M)(23.17M)(22.12M)[{"date":"2019-12-31","value":-1119500000,"profit":false},{"date":"2020-12-31","value":-1501800000,"profit":false},{"date":"2021-12-31","value":-2453200000,"profit":false},{"date":"2022-12-31","value":-2316900000,"profit":false},{"date":"2023-12-31","value":-2212378500,"profit":false}]
Income From Continuous Operations(11.20M)(15.02M)(24.53M)(23.17M)(24.47M)[{"date":"2019-12-31","value":-1119500000,"profit":false},{"date":"2020-12-31","value":-1501800000,"profit":false},{"date":"2021-12-31","value":-2453200000,"profit":false},{"date":"2022-12-31","value":-2316900000,"profit":false},{"date":"2023-12-31","value":-2447400000,"profit":false}]
Income From Discontinued Operations-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Net Income(11.20M)(15.02M)(24.53M)(23.17M)(22.13M)[{"date":"2019-12-31","value":-1119500000,"profit":false},{"date":"2020-12-31","value":-1501800000,"profit":false},{"date":"2021-12-31","value":-2453200000,"profit":false},{"date":"2022-12-31","value":-2316900000,"profit":false},{"date":"2023-12-31","value":-2212500000,"profit":false}]
EPS (Diluted)-(0.19)(1.25)(3.59)(2.26)[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":-19,"profit":false},{"date":"2021-12-31","value":-125,"profit":false},{"date":"2022-12-31","value":-359,"profit":false},{"date":"2023-12-31","value":-226,"profit":false}]

Ratios

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

EVAX
ROA (LTM) -69.45%
ROE (LTM) -802.80%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

EVAX
Debt Ratio Lower is generally better. Negative is bad. 1.00
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.00

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

EVAX
Trailing PE NM
Forward PE 3.57
P/S (TTM) 1.51
P/B 336.90
EV/R 8.32
EV/Ebitda NM

FAQs

What is Evaxion Biotech AS share price today?

Evaxion Biotech AS (EVAX) share price today is $3.7791

Can Indians buy Evaxion Biotech AS shares?

Yes, Indians can buy shares of Evaxion Biotech AS (EVAX) on Vested. To buy Evaxion Biotech AS from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in EVAX stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Evaxion Biotech AS be purchased?

Yes, you can purchase fractional shares of Evaxion Biotech AS (EVAX) via the Vested app. You can start investing in Evaxion Biotech AS (EVAX) with a minimum investment of $1.

How to invest in Evaxion Biotech AS shares from India?

You can invest in shares of Evaxion Biotech AS (EVAX) via Vested in three simple steps:

  • Click on Sign Up or Invest in EVAX stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Evaxion Biotech AS shares
What is Evaxion Biotech AS 52-week high and low stock price?

The 52-week high price of Evaxion Biotech AS (EVAX) is $68.05. The 52-week low price of Evaxion Biotech AS (EVAX) is $3.32.

What is Evaxion Biotech AS price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of Evaxion Biotech AS (EVAX) is

What is Evaxion Biotech AS price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Evaxion Biotech AS (EVAX) is 336.90

What is Evaxion Biotech AS dividend yield?

The dividend yield of Evaxion Biotech AS (EVAX) is 0.00%

What is the Market Cap of Evaxion Biotech AS?

The market capitalization of Evaxion Biotech AS (EVAX) is $22.17M

What is Evaxion Biotech AS’s stock symbol?

The stock symbol (or ticker) of Evaxion Biotech AS is EVAX

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top